Shield Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Shield Therapeutics's earnings have been declining at an average annual rate of -41.1%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 10.4% per year.
Belangrijke informatie
-41.1%
Groei van de winst
-15.3%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 14.1% |
| Inkomstengroei | 10.4% |
| Rendement op eigen vermogen | -6,685.0% |
| Nettomarge | -168.4% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15Opbrengsten en kosten
Hoe Shield Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 21 | -36 | 40 | 2 |
| 31 Mar 24 | 17 | -35 | 39 | 2 |
| 31 Dec 23 | 13 | -33 | 38 | 2 |
| 30 Sep 23 | 10 | -40 | 36 | 1 |
| 30 Jun 23 | 7 | -47 | 36 | 0 |
| 31 Mar 23 | 6 | -49 | 35 | 1 |
| 31 Dec 22 | 5 | -50 | 34 | 1 |
| 30 Sep 22 | 5 | -39 | 32 | 1 |
| 30 Jun 22 | 4 | -30 | 32 | 0 |
| 31 Mar 22 | 3 | -29 | 30 | 1 |
| 31 Dec 21 | 2 | -27 | 27 | 1 |
| 30 Sep 21 | 2 | -22 | 20 | 3 |
| 30 Jun 21 | 3 | -18 | 14 | 5 |
| 31 Mar 21 | 9 | -11 | 13 | 4 |
| 31 Dec 20 | 14 | -4 | 12 | 4 |
| 30 Sep 20 | 13 | -3 | 11 | 3 |
| 30 Jun 20 | 11 | -2 | 10 | 2 |
| 31 Mar 20 | 6 | -6 | 9 | 3 |
| 31 Dec 19 | 1 | -12 | 9 | 3 |
| 30 Sep 19 | 8 | -4 | 10 | 4 |
| 30 Jun 19 | 15 | 3 | 12 | 4 |
| 31 Mar 19 | 15 | 0 | 14 | 5 |
| 31 Dec 18 | 15 | -2 | 16 | 5 |
| 30 Sep 18 | 8 | -13 | 18 | 6 |
| 30 Jun 18 | 1 | -24 | 20 | 6 |
| 31 Mar 18 | 1 | -26 | 22 | 7 |
| 31 Dec 17 | 1 | -26 | 23 | 6 |
| 30 Sep 17 | 1 | -24 | 20 | 5 |
| 30 Jun 17 | 0 | -21 | 18 | 4 |
| 31 Mar 17 | 0 | -19 | 15 | 3 |
| 31 Dec 16 | 0 | -19 | 13 | 3 |
| 30 Sep 16 | 0 | -12 | 11 | 4 |
| 30 Jun 16 | 0 | -4 | 8 | 6 |
| 31 Mar 16 | 0 | -19 | 5 | 7 |
| 31 Dec 15 | 0 | -35 | 2 | 8 |
| 30 Sep 15 | 0 | -41 | 2 | 6 |
| 30 Jun 15 | 0 | -49 | 2 | 4 |
| 31 Mar 15 | 0 | -33 | 2 | 4 |
| 31 Dec 14 | 0 | -20 | 2 | 4 |
| 31 Dec 13 | 0 | -7 | 2 | 5 |
Kwaliteitswinsten: STX is currently unprofitable.
Groeiende winstmarge: STX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: STX is unprofitable, and losses have increased over the past 5 years at a rate of 41.1% per year.
Versnelling van de groei: Unable to compare STX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: STX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).
Rendement op eigen vermogen
Hoge ROE: STX has a negative Return on Equity (-6685.03%), as it is currently unprofitable.